Ketamine and other NMDA receptor antagonists for chronic pain: protocol

Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/26086

Title:	Ketamine and other NMDA receptor antagonists for chronic pain: protocol
Authors:	Ferraro, MC Cashin, AG O'Connell, NE Visser, E Abdel Shaheed, C Wewege, MA Gustin, SM McAuley, JH
Advisors:	The Cochrane Collaboration
Issue Date:	23-Feb-2023
Publisher:	John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration
Citation:	Ferraro, M.C. et al. (2023) 'Ketamine and other NMDA receptor antagonists for chronic pain: protocol', Cochrane Database of Systematic Reviews, 2023 (2), Art. No.: CD015373, pp. i, 1 - 13. doi: 10.1002/14651858.CD015373.
Abstract:	Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of ketamine and other NDMA receptor antagonists compared to placebo, usual care, or other medicines for adults with chronic non‐cancer pain.
URI:	https://bura.brunel.ac.uk/handle/2438/26086
DOI:	https://doi.org/10.1002/14651858.CD015373
ISSN:	1465-1858
Other Identifiers:	ORCiD: Neil O'Connell https://orcid.org/0000-0003-1989-4537 Article number: CD015373
Appears in Collections:	Dept of Health Sciences Research Papers

Files in This Item:

File	Description	Size	Format
FullText.pdf	Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Green open access: free access to the full article 12 months after publication and the standard publication licence (see: https://www.cochranelibrary.com/about/open-access#Green%20OA).	206.55 kB	Adobe PDF	View/Open